Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating the use of EEG-based Brain-Computer Interface BCI technology to detect awareness and enable communication in people with prolonged disorders of consciousness DoC, such as unresponsive wakefulness syndrome UWS, minimally conscious state MCS, and locked-in syndrome LIS. The study aims to improve diagnosis accuracy where traditional methods relying on motor responses may fail, and to explore if BCI can provide movement-independent communication. The trial also investigates whether training with BCI can enhance brain response consistency and communication ability. Participants undergo three phases Phase I assesses if patients can imagine movements and produce detectable brain activity using EEG. Phase II involves training with motor imagery BCI and real-time auditory feedback to help participants modulate brain signals. Phase III tests participants ability to answer yes-no questions using imagined movement patterns. The study uses specific imagined movement combinations to represent yes or no responses, tailored individually and applied throughout sessions lasting about 1.5 hours each. During the study, participants complete up to 10 sessions including assessments, training, and communication tasks. Researchers monitor changes in BCI performance accuracy, ability to communicate consistently, and clinical scale scores related to consciousness and recovery. The study evaluates how feedback types and timing affect performance and collects data to support clinical diagnosis and potential therapeutic benefits. Participation involves EEG recordings, neurofeedback, and answering structured questions over several weeks.
Actively Recruiting
Researchers are investigating whether certain approved drugs can slow the progression and improve survival in people with motor neuron disease MND, including amyotrophic lateral sclerosis and related subtypes. This trial uses a multi-arm adaptive design, allowing new drugs to be added and ineffective ones to be dropped over time. The study began with memantine, trazodone, and placebo arms, with amantadine and tacrolimus added later, and the first two drugs removed due to lack of benefit. Participants are randomly assigned to one of several groups, including amantadine, tacrolimus, or matching placebos taken once daily as either oral solutions or capsules. The adaptive approach enables evaluation of each drug against placebo efficiently. The trial started in February 2020 and continues recruiting with ongoing adjustments to treatments based on emerging results. During participation, individuals will be monitored over 18 months with regular assessments including ALS functional rating scales, survival analysis, cognition, respiratory function, clinical staging, anxiety and depression evaluations, quality of life measurements, and safety monitoring. Data collection involves questionnaires and clinical tests to track disease progression and treatment effects, with careful attention to tolerability and adverse events throughout the study period.
Actively Recruiting
Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.